Granted Patent B2

US 12,491,166 · App. 17/460,820 · Granted Dec 9, 2025

Inventors: Amitabha Mitra (Saline, MI); Megan Gutman (Fraser, MI); Megan Zarembski (Ann Arbor, MI); Johanna Koch (Munich, DE); Ryan Hollingsworth (Canton, MI)

A61K9/7069A61K31/658

Abstract

Claims (10)

1 . A method of delivering an active compound, comprising:

providing a delivery device for delivery of an active compound to skin having a first portion defining first outer surface of the device being skin facing surface, the first portion being a siloxane gel and defining a first outer surface of the device, the first outer surface being configured to contact the skin and deliver the active compound thereto, wherein the siloxane gel is formed from a mixture comprising a first polysiloxane, a second polysiloxane, and a hydrosilylation catalyst, the first polysiloxane being an alkenyl-substituted polysiloxane and the second polysiloxane comprising silicon-bonded hydrogen atoms, and wherein the active compound is chosen from the group consisting of a cannabinoid and melatonin; and

forming the first portion by providing the active compound in the first portion and, with the active compound within the first portion, curing the first portion to form the siloxane gel, wherein the first outer surface exhibits a first tack after providing the active compound and a second tack of at least 25 percent the first tack after delivering the active compound to the first outer surface.

2 . The method of claim 1 , wherein the second tack is at least 50 percent the first tack after delivering the active compound to the first outer surface.

3 . The method of claim 1 , wherein the second tack is at least 50 percent the first tack.

4 . The method of claim 1 , wherein the delivery device further comprises a backing layer, the backing layer defining a second outer surface of the delivery device and being attached directly to the first portion.

5 . The method of claim 1 , wherein the delivery device is a transdermal delivery device and the method further comprises delivering the active compound to the skin and bloodstream of a user of the delivery device.

6 . The method of claim 1 , further comprising forming the first portion from a mixture comprising a first polysiloxane, a second polysiloxane, and a hydrosilylation catalyst, the first polysiloxane being an alkenyl-substituted polysiloxane comprising one or more silicon-bonded vinyl (SiVi) groups and the second polysiloxane comprising one or more silicon-bonded hydrogen (SiH) groups and the ratio of SiVi:SiH groups is 10:1 to 1:10.

7 . The method of claim 1 , wherein the active compound is a cannabinoid.

8 . The method of claim 6 , wherein the ratio of SiVi:SiH groups is about 1:1.

Assignments (1)

Continuity (2)

References Cited (39)